The FDA-cleared BIOFIRE RP2.1 Panel is a multiplex PCR test that identifies 22 pathogens associated with respiratory infections. Designed to provide fast, comprehensive results, this panel helps clinicians make fast and informed decisions for patient management.
Viruses
- Adenovirus
- Coronavirus 229E
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus OC43
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Human metapneumovirus
- Human rhinovirus/enterovirus
- Influenza A virus
- Influenza A virus A/H1
- Influenza A virus A/H3
- Influenza A virus A/H1-2009
- Influenza B virus
- Parainfluenza virus 1
- Parainfluenza virus 2
- Parainfluenza virus 3
- Parainfluenza virus 4
- Respiratory syncytial virus
Bacteria
- Bordetella parapertussis
- Bordetella pertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae
- Technology: Multiplex PCR-based molecular diagnostics (syndromic approach)
- Format: Single, self-contained, freeze-dried reagent pouch
- Sample Type: Nasopharyngeal swab
- Result Time: Approximately 45 minutes
- Ease of Use: Automated workflow from sample to result, requiring minimal hands-on time
The BIOFIRE RP2.1 Panel is a frontline test to help clinicians more quickly diagnose URTIs1, including COVID-19, influenza, RSV, and others. This test provides the essential combination of speed, accuracy, and comprehensiveness to enable a rapid, definitive identification of a pathogen.
Related Products
- Kitano, T. et. al., (2020) J Infect Chemother. 26 (1):82-85
Contact Us
Eager to advance your biothreat detection and infectious disease diagnostic capabilities? Connect with us to discuss how BioFire can help strengthen your preparedness and accelerate your response in critical situations.